Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer

Journal of Clinical Oncology

Volumn 33, Issue 19, 2015, Pages 2143-2150

  Mason, Malcolm D ^a   Parulekar, Wendy R ^j   Sydes, Matthew R ^c   Brundage, Michael ^k   Kirkbride, Peter ^d   Gospodarowicz, Mary ^l   Cowan, Richard ^e   Kostashuk, Edmund C ⁿ   Anderson, John ^f   Swanson, Gregory ^r   Parmar, Mahesh K B ^c   Hayter, Charles ^m   Jovic, Gordana ^c   Hiltz, Andrea ^j   Hetherington, John ^g   Sathya, Jinka ^p   Barber, James B P ^b   McKenzie, Michael ^o   El Sharkawi, Salah ^h   Souhami, Luis ^q   Hardman, P D John ⁱ   Chen, Bingshu E ^j   Warde, Padraig ^l   more..

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b VELINDRE CANCER CENTRE   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^g CASTLE HILL HOSPITAL   (United Kingdom)

^h South West Wales Cancer Centre ^*  (United Kingdom)

ⁱ JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^j QUEEN S UNIVERSITY   (Canada)

^k Cancer Centre of Southeastern Ontario   (Canada)

^l PRINCESS MARGARET HOSPITAL   (Canada)

^m UNIVERSITY OF TORONTO   (Canada)

ⁿ Fraser Valley Cancer Centre   (Canada)

^o Vancouver Cancer Centre   (Canada)

^p MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^q MCGILL UNIVERSITY   (Canada)

^r UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; ADVANCED CANCER; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BLEEDING; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CONTROLLED STUDY; DIARRHEA; DISEASE SPECIFIC SURVIVAL; ENTEROPATHY; FLATULENCE; GLEASON SCORE; HEART MUSCLE ISCHEMIA; HOT FLUSH; HUMAN; HYPERTENSION; IMPOTENCE; INTERMETHOD COMPARISON; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; OVERALL SURVIVAL; PAIN; PRIORITY JOURNAL; PROCTITIS; PROSTATE CANCER; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; BLOOD; CANCER GRADING; CAUSE OF DEATH; CHEMORADIOTHERAPY; DISEASE COURSE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CAUSE OF DEATH; CHEMORADIOTHERAPY; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84937533769     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.57.7510     Document Type: Article

References (33)

1. Center MM, Jemal A, Lortet-Tieulent J, et al: International variation in prostate cancer incidence and mortality rates. Eur Urol 61:1079-1092, 2012
2. Ward JF, Slezak JM, Blute ML, et al: Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 95:751-756, 2005
3. Fellows GJ, Clark PB, Beynon LL, et al: Treatment of advanced localised prostatic cancer by orchiectomy, radiotherapy, or combined treatment: A Medical Research Council Study - Urological Cancer Working Party-Subgroup on Prostatic Cancer. Br J Urol 70:304-309, 1992
4. Mason MD, Brewster S, Moffat LE, et al: Randomized trials in early prostate cancer: II. Hormone therapy and radiotherapy for locally advanced disease: A question is still unanswered. Clin Oncol (R Coll Radiol) 12:215-216, 2000
5. Bolla M, de Reijke TM, Van Tienhoven G, et al: Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360:2516-2527, 2009
6. Pilepich MV, Winter K, Lawton CA, et al: Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma: Long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61:1285-1290, 2005
7. Pilepich MV, Winter K, John MJ, et al: Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50:1243-1252, 2001
8. Warde P, Mason M, Ding K, et al: Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: A randomised, phase 3 trial. Lancet 378:2104-2111, 2011
9. Brundage M, Sydes MR, Parulekar WR, et al: Impact of radiotherapy when added to androgen-deprivation therapy for locally advanced prostate cancer: Long-term quality-of-life outcomes from the NCIC CTC PR3/MRC PR07 randomized trial. J Clin Oncol 33:2151-2157, 2015
10. Roach M 3rd, Hanks G, Thames H Jr, et al: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65:965-974, 2006
11. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:103-115, 1975
12. Monti AF, Ostinelli A, Frigerio M, et al: An ICRU 50 radiotherapy treatment chart. Radiother Oncol 35:145-150, 1995
13. DeMets DL, Lan G: The alpha spending function approach to interim data analyses. Cancer Treat Res 75:1-27, 1995
14. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
15. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
16. Widmark A, Klepp O, Solberg A, et al: Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): An open randomised phase III trial. Lancet 373:301-308, 2009
17. Mottet N, Peneau M, Mazeron JJ, et al: Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: An open randomised phase 3 trial. Eur Urol 62:213-219, 2012
18. Dearnaley DP, Sydes MR, Graham JD, et al: Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial. Lancet Oncol 8:475-487, 2007
19. Kuban DA, Tucker SL, Dong L, et al: Longterm results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70:67-74, 2008
20. Al-Mamgani A, van Putten WL, Heemsbergen WD, et al: Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 72:980-988, 2008
21. Zelefsky MJ, Pei X, Chou JF, et al: Dose escalation for prostate cancer radiotherapy: Predictors of long-term biochemical tumor control and distant metastases-free survival outcomes. Eur Urol 60:1133-1139, 2011
22. Arcangeli S, Strigari L, Gomellini S, et al: Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 84:1172-1178, 2012
23. Hanks GE, Buzydlowski J, Sause WT, et al: Ten-year outcomes for pathologic node-positive patients treated in RTOG 75-06. Int J Radiat Oncol Biol Phys 40:765-768, 1998
24. Lawton CA, DeSilvio M, Roach M 3rd, et al: An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: Updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 69:646-655, 2007
25. Pommier P, Chabaud S, Lagrange JL, et al: Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol 25:5366-5373, 2007
26. Kim J, Vaid M, Tyldesley S, et al: Population-based study of cardiovascular mortality among patients with prostate cancer treated with radical external beam radiation therapy with and without adjuvant androgen deprivation therapy at the British Columbia Cancer Agency. Int J Radiat Oncol Biol Phys 80:742-750, 2011
27. Faris JE, Smith MR: Metabolic sequelae associated with androgen deprivation therapy for prostate cancer. Curr Opin Endocrinol Diabetes Obes 17:240-246, 2010
28. Keating NL, O'Malley AJ, Smith MR: Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24:4448-4456, 2006
29. Mitchell CR, Boorjian SA, Umbreit EC, et al: 20-Year survival after radical prostatectomy as initial treatment for cT3 prostate cancer. BJU Int 110:1709-1713, 2012
30. Lowrance WT, Elkin EB, Yee DS, et al: Locally advanced prostate cancer: A population-based study of treatment patterns. BJU Int 109:1309-1314, 2012
31. Cooperberg MR, Broering JM, Carroll PR: Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 28:1117-1123, 2010
32. European Association of Urology: Homepage. http://www.uroweb.org
33. National Comprehensive Cancer Network: Clinical practice guidelines in oncology: Prostate cancer (version 1.2015). http://www.nccn.org/professionals/physician-gls/pdf/prostate.pdf